Topical Treatment of Atopic Dermatitis
의약학 > 피부과학
( Jong Rok Lee )
한국피부장벽학회지 2012년, 제14권 제1호, 58~62페이지(총5페이지)
1j700313.pdf [무료 PDF 뷰어 다운로드]
  • ※ 본 자료는 참고용 논문으로 수정 및 텍스트 복사가 되지 않습니다.
  • 구매가격
    135원 (구매자료 3% 적립)
    이메일 발송  스크랩 하기
    자료 다운로드  네이버 로그인
    Atopic dermatitis is a chronic, pruritic, inflammatory skin disease with a wide range of severity. It is one of the most common skin disorders in developed countries, affecting approximately 20% of children and 1-3% of adults. Severe eczematous skin lesion and itching can significantly affect the quality of life of the patient. Best clinical practice in the management of AD requires a multi-therapeutic approach that includes short-term treatment of AD flares and longer-term treatment that control symptoms between flares and prolong the time to next flare. Therapies used include emollients, topical corticosteroid, and topical calcineurin inhibitors (TCIs). Emollients have long been used to maintain the skin barrier function in patients with AD. Topical corticosteroids have been the pillar of medicated therapy for AD since their introduction nearly 50years ago, Topical calcineurin inhibitors represented the first new class of medication approved for the treatment of AD since topical corticosteroid, TCIs provide targeted anti-inflammatory activity without the local or systemic side-effects seen with topical corticosteroid, More recently, three new nosteroidal barrier cream have entered the marketplace for AD treatment. Multiple topical therapies have been successfully used to treat patients with AD. An understanding of the available treatment options will help primary care providers striving to achieve best practice in the management of AD.
    오늘 본 자료
    • 오늘 본 자료가 없습니다.
    본 학술논문은 한국학술정보㈜ 각 학회간에 저작권 계약이 체결된 것으로 HAPPY학술이 제공하고 있습니다.
    본 저작물을 불법적으로 이용시는 법적인 제재가 가해질 수 있습니다.
    사업자등록번호 220-87-87785 대표.신현웅 주소.서울시 서초구 방배로10길 18, 402호 대표전화.070-8809-9397
    개인정보책임자.박정아 통신판매업신고번호 제2017-서울서초-1765호 이메일
    copyright (c) 2009 happynlife. steel All reserved.